TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting
Poster Presentation: |
||
Abstract Title: | ENVASARC: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma who have Progressed on Prior Chemotherapy | |
Abstract Number: | TPS11581 | |
Poster Session: | Sarcoma | |
Session Start: | ||
Poster Discussion Session: | ||
Abstract Title: | Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of Uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer | |
Abstract Number: | 2511 | |
Poster Session: | Development Therapeutics-Immunotherapy | |
Session Start: |
The posters will be available on the publications page of the company’s website following presentation.
About Envafolimab
Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in pivotal trials. Envafolimab is currently being studied in the ENVASARC Phase 2 pivotal trial in the
About ENVASARC (NCT04480502)
The ENVASARC pivotal trial is a multi-center, open label, randomized, non-comparative, parallel cohort study at approximately 25 top cancer centers in
About TJ004309
TJ004309 is a novel, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is highly immunosuppressive. TJ004309 is currently being studied in an ongoing Phase 1 trial to assess safety and preliminary efficacy as a single agent and when combined with the PD-L1 checkpoint inhibitor Tecentriq in patients with advanced solid tumors.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads
Company Contact: | Investor Contact: |
Chief Business Officer | |
858-251-3492 | 212-915-2578 |
mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
Source: TRACON Pharmaceuticals, Inc.